35.37

0.65% 0.23

After Hours: 35.37

Vericel Corp (VCEL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vericel Corp stock is traded at $35.37, with a volume of 364.33K. It is up +0.65% in the last 24 hours and up +8.71% over the past month. Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Previous Close:

$35.14

Open:

$34.89

24h Volume:

364.33K

Relative Volume:

0.63

Market Cap:

$1.80B

Revenue:

$276.26M

Net Income/Loss:

$16.52M

P/E Ratio:

114.91

EPS:

0.3078

Net Cash Flow:

$24.75M

1W Performance:

+3.94%

1M Performance:

+8.71%

6M Performance:

+5.30%

1Y Performance:

-15.82%

1-Day Range:

$34.83

$35.52

1-Week Range:

$32.99

$35.52

52-Week Range:

$28.95

$45.97

Vericel Corp Stock (VCEL) Company Profile

Name

Vericel Corp

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(734) 930-5555

Address

64 SIDNEY ST., CAMBRIDGE, MA

Employee

398

Twitter

@VericelCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

VCEL's Discussions on Twitter

Compare VCEL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCEL Vericel Corp	35.37	1.79B	276.26M	16.52M	24.75M	0.3078
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Vericel Corp Stock (VCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy
Jun-20-24	Initiated	TD Cowen	Buy
Jan-25-24	Upgrade	Truist	Hold → Buy
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight
Sep-17-20	Initiated	Truist	Buy
Oct-09-19	Initiated	H.C. Wainwright	Buy
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-06-18	Reiterated	Needham	Buy
Mar-05-18	Reiterated	BTIG Research	Buy
Jun-21-17	Initiated	BTIG Research	Buy
Mar-13-17	Reiterated	Needham	Buy
Dec-22-16	Initiated	Piper Jaffray	Overweight
Nov-09-16	Reiterated	Needham	Buy
Apr-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Mar-11-16	Upgrade	Needham	Hold → Buy

View All

Vericel Corp Stock (VCEL) Latest News

01:20 AM

VCEL Maintains Buy Rating -- Price Target Lowered to $42 by Trui - GuruFocus

01:20 AM

09:27 AM

Truist Cuts Price Target on Vericel to $42 From $48, Keeps Buy Rating - marketscreener.com

09:27 AM

08:05 AM

Vericel Corporation (VCEL) secures FDA approval for commercial manufacturing of MACI - MSN

08:05 AM

Apr 14, 2026

Critical Limb Ischemia Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Baxter, Ixaka, Hemostemix Inc., Caladrius Biosciences, Vericel Corporation, Helixmith, Lifecells, LLC - Barchart.com

Apr 14, 2026

Apr 11, 2026

Assessing Vericel (VCEL) Valuation After BARDA Awards Up To US$197 Million NexoBrid Contract - simplywall.st

Apr 11, 2026

Apr 10, 2026

Q3 2025 Vericel Corp Earnings Call Transcript - GuruFocus

Apr 10, 2026

Apr 08, 2026

Winners Losers: What are the future prospects of Vericel Corporation2026 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Weekly Trades: Is Vericel Corporation part of any ETF2026 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Jonathan Mark Hopper Sells 3,472 Shares of Vericel (NASDAQ:VCEL) Stock - MarketBeat

Apr 06, 2026

Vericel (VCEL) CMO sells 3,472 shares after option exercise under 10b5-1 plan - Stock Titan

Apr 06, 2026

Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Cantech Letter

Apr 06, 2026

After islet transplants, 10 diabetes patients stopped using insulin - Stock Titan

Apr 06, 2026

Aberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCEL - MarketBeat

Apr 06, 2026

Analysts Set Vericel Corporation (NASDAQ:VCEL) Price Target at $56.00 - Defense World

Apr 06, 2026

Apr 04, 2026

Vericel Corporation (VCEL) Stock forecasts - Yahoo Finance UK

Apr 04, 2026

VCEL SEC FilingsVericel 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Allspring Global Investments Holdings LLC Cuts Position in Vericel Corporation $VCEL - marketbeat.com

Apr 04, 2026

Apr 03, 2026

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

Apr 03, 2026

Vericel Corporation (VCEL) Stock Forecasts - Yahoo Finance

Apr 03, 2026

Vericel Corporation (NASDAQ:VCEL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 03, 2026

Vericel at TD Cowen Conference: Strong Growth and Strategic Expansion By Investing.com - Investing.com India

Apr 03, 2026

Apr 02, 2026

Vericel at TD Cowen Conference: Strong Growth and Strategic Expansion - Investing.com

Apr 02, 2026

Vericel (VCEL) Secures Lucrative Contract with Health and Human Services - GuruFocus

Apr 02, 2026

MediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and Development - Quiver Quantitative

Apr 02, 2026

U.S. stockpile plans include NexoBrid under BARDA deal worth up to $197M - Stock Titan

Apr 02, 2026